Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease

Simple item page
dc.contributor.authorArturo J Martí-Carvajal
dc.contributor.authorIván Solà
dc.contributor.authorPedro I. Marti-Carvajal
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:05:35Z
dc.date.available2026-03-22T21:05:35Z
dc.date.issued2012
dc.descriptionCitaciones: 9
dc.description.abstractNo randomised clinical trials assessing the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease were identified. The benefits and harms of antifibrinolytic amino acids need to be tested in randomised clinical trials. Unless randomised clinical trials are conducted to assess the trade off between benefits and harms, we cannot recommend nor refute antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseases.
dc.identifier.doi10.1002/14651858.cd006007.pub3
dc.identifier.urihttps://doi.org/10.1002/14651858.cd006007.pub3
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/85884
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofCochrane Database of Systematic Reviews
dc.sourceIberoamerican Cochrane Centre
dc.subjectMedicine
dc.subjectAntifibrinolytic
dc.subjectCochrane Library
dc.subjectClinical trial
dc.subjectInternal medicine
dc.subjectRandomized controlled trial
dc.subjectLiver disease
dc.subjectTranexamic acid
dc.subjectIntensive care medicine
dc.titleAntifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease
dc.typereview

Files

Collections

Artículo Científico Publicado